House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Infectious diseases

Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing

NICE · 2021 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

NICE NG190 guides antibiotic decisions when eczema may have a secondary bacterial infection. It emphasizes continuing eczema treatment, avoiding routine antibiotics in people who are not systemically unwell, and reassessing deterioration for alternative diagnoses or serious infection. Antibiotic choice depends on clinical severity, distribution and local resistance; the prescribing tables describe UK practice and require local formulary adaptation.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Recognize infection without treating colonisation

  • Weeping, pustules, crusting, treatment nonresponse, rapid worsening, fever and malaise can suggest secondary bacterial infection. However, weeping or crusting alone does not establish infection: eczema may be colonised, and nonbacterial flares will not respond to antibiotics. [1]
  • Continue treatment of the underlying eczema and flares with emollients and topical corticosteroids whether antibiotics are prescribed or not. Herpes simplex infection can also complicate eczema, and cellulitis requires its own treatment pathway. [1]
  • Do not routinely obtain an initial skin swab for microbiology when secondary bacterial infection of eczema first presents. Later testing is guided by failure to improve or recurrence. [1]

Decide whether antibiotics are warranted

  • Do not routinely offer topical or oral antibiotics to people who are not systemically unwell. Consider the limited additional benefit over topical corticosteroids, resistance from repeated courses, extent and severity, and increased complication risk with conditions such as immunosuppression. [1]
  • If prescribing despite the person not being systemically unwell, localized nonsevere infection may favour topical treatment, while widespread or severe infection may favour oral treatment. Include preferences, adverse effects and previous topical-antibiotic exposure in the decision. [1]
  • Offer an oral antibiotic when the person is systemically unwell with secondary bacterial infection of eczema. Reassess the need for referral or specialist advice alongside treatment. [1]

Explain the plan and safety net

  • When withholding antibiotics, explain why they are unlikely to help and advise seeking medical attention if symptoms worsen rapidly or significantly at any time. [1]
  • When prescribing, explain adverse effects and resistance risk, continue eczema treatments, and explain that complete resolution may occur only after the course is finished. Rapid or significant deterioration still requires prompt medical help. [1]

Reassess deterioration and recurrent infection

  • Reassess new systemic illness, pain out of proportion, rapid or significant worsening, or failure to improve after antibiotics. Consider eczema herpeticum, cellulitis, necrotising fasciitis, sepsis and resistant organisms after prior antibiotic use. [1]
  • Consider a skin swab when infection worsens or fails to improve as expected. With frequent recurrence, send a skin swab and consider a nasal swab and decolonisation treatment. [1]
  • Review microbiology when available. If symptoms are not improving, change the antibiotic according to results, using a narrow-spectrum agent where possible. [1]
  • Refer to hospital when signs suggest necrotising fasciitis or sepsis. Consider referral or specialist advice for spreading infection unresponsive to oral antibiotics, systemic illness, high complication risk or frequent recurrence. [1]

Use the appropriate prescribing table

  • Account for local resistance data. NICE separates adult and pediatric prescribing, and antibiotic selection in infants under 1 month should be based on specialist advice. [1]
  • For adults requiring topical treatment of localized infection, NICE lists fusidic acid 2% three times daily for 5 to 7 days. Extended or recurrent courses increase resistance risk. Where oral therapy is appropriate, its first choice is flucloxacillin 500 mg four times daily for 5 to 7 days. [1]
  • For nonpregnant adults with penicillin allergy or unsuitable flucloxacillin, NICE lists clarithromycin 250 mg twice daily for 5 to 7 days, increasing to 500 mg twice daily for severe infection. In pregnancy, erythromycin is preferred if a macrolide is needed and treatment benefits outweigh harms. [1]
  • Suspected or confirmed meticillin-resistant Staphylococcus aureus requires microbiologist advice. Use the full prescribing reference for renal or hepatic impairment, pregnancy and breastfeeding; pediatric age bands also require attention to the child’s size and illness severity. [1]

Do not extrapolate the eczema evidence

  • NICE found no evidence on antibiotics for secondary bacterial infection of psoriasis, chickenpox, shingles or scabies. Seek specialist advice when needed rather than assuming the eczema recommendations establish an equivalent evidence base. [1]

Limitations and use

  • This summary does not reproduce the complete pediatric dose table or individual prescribing adjustments; consult the appropriate age- and weight-specific reference.
  • Cellulitis and eczema herpeticum need their own diagnostic and treatment pathways.
  • NICE antibiotic choices reflect UK guidance; availability and local antimicrobial resistance must inform application in India.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
2 March 2021
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Recognize infection without treating colonisation
  • Decide whether antibiotics are warranted
  • Explain the plan and safety net
  • Reassess deterioration and recurrent infection
  • Use the appropriate prescribing table
  • Do not extrapolate the eczema evidence
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House